Nektar Therapeutics expected to post a loss of 21 cents a share - Earnings Preview

Nektar Therapeutics

02/11/2024 04:04

* Nektar Therapeutics  NKTR.OQ   NKTR.O  is expected to show
a
fall in quarterly revenue when it reports  results on November 7
for the period ending September 30 2024
    * The San Francisco California-based  company is expected to
report a 24.3% decrease in revenue to $18.284 million from
$24.14 million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Nektar Therapeutics is
for a
loss of 21 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nektar
Therapeutics is 2.65​, above​ its last closing price of $1.23.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.19       -0.20      -0.25     Missed  -22.8
 Mar. 31 2024  -0.19       -0.19      -0.19     Met     0
 Jan. 1 0001   -0.22       -0.21      -0.22     Missed  -3.6​
 Sep. 30 2023  -0.21       -0.20      -0.24     Missed  -20.3
 ​​Jun.        -0.31       -0.28      -0.27     Beat    4.9
 30 2023                                                
 Mar. 31 2023  -0.23       -0.25      -0.32     Missed  -26.7​
 Dec. 31 2022  -0.44       -0.45      -0.32     Beat    29.3
 Jan. 1 0001   -0.49       -0.45      -0.31     Beat    31
 This summary was machine generated November 2 at 04:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)